Welcome to our dedicated page for MSP Recovery SEC filings (Ticker: MSPR), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
MSP Recovery, Inc. filings document the company's reimbursement recovery business and its public-company capital structure. Recent Form 8-K reports center on material definitive agreements involving subsidiary funding arrangements, working capital credit facility disclosures and operating-expense financing. The filings identify Class A common stock and redeemable warrants traded on the OTC Market Group under MSPR, MSPRW and MSPRZ.
The company's regulatory record also includes reporting-status disclosures, including a Form 12b-25 notification related to a delayed annual report. Those filings describe liquidity constraints, reliance on loan funding, evaluation of financing and reorganization alternatives, and risks around continued reporting. Periodic reports and current reports provide formal disclosure on governance, capital structure, material agreements, risk factors and the financial reporting framework for MSP Recovery's recovery and technology operations.
MSP Recovery (MSPR) filed Prospectus Supplement No. 51 registering for resale up to 909,982 shares of Class A common stock, the resale of up to 755,200,000 warrants, and the potential issuance of up to 236,019 shares upon warrant exercise, after effectiveness and subject to terms described. The company expects only nominal proceeds from Public Warrant exercises and states it will not retain any proceeds from exercises of the New Warrants.
The supplement attaches a Current Report that updates financing and listing developments. The Floor Price under the Yorkville standby equity facility and related convertible notes was reduced to $0.50. Yorkville advanced a $0.50 million convertible note (net proceeds $0.45 million) with a conversion price based on 95% of the lowest five-day VWAP, not below the $0.50 floor, and subject to a 9.99% ownership cap. The Nomura promissory note was amended to reflect approximately $35.4 million principal and to permit up to $3.0 million of Yorkville convertible-note proceeds to fund operations. Nasdaq issued a delisting determination with trading suspension set for October 31, 2025; MSPR will request a panel review.
MSP Recovery, Inc. filed Prospectus Supplement No. 44 for the resale of up to 32,220 shares of Class A Common Stock by selling securityholders, including up to 15,239 shares issuable upon exercise of the CPIA Warrant at an exercise price of $0.4375 per share. The company will not receive proceeds from sales by the selling holders; it would receive only nominal proceeds if the CPIA Warrant is exercised.
The supplement attaches a Current Report on Form 8-K. The company and Yorkville reduced the SEPA floor price from $1.00 to $0.50 and Yorkville advanced a $0.50 million convertible note on October 28, 2025, resulting in net proceeds of $0.45 million. Convertible notes may convert at the lower of a fixed price or 95% of the lowest daily VWAP over five days, not below the $0.50 floor, subject to a 9.99% ownership cap. The Nomura note was amended to reflect approximately $35.4 million principal and to allow up to $3.0 million of SEPA proceeds to fund operations. Nasdaq issued a delisting determination on October 22, 2025; the company intends to request a panel review.
MSP Recovery (MSPR) filed Prospectus Supplement No. 33 covering the resale of up to 56,896 shares of Class A common stock by selling securityholders. The shares include up to 28,572 issuable upon exercise of VRM warrants, 2,858 issued to VRP and up to 14,286 issuable upon exercise of a VRP warrant, and 11,180 issued to Palantir. With a warrant exercise price of $0.0175 per share, the company would receive only nominal proceeds upon any warrant exercises; it would not receive proceeds from selling stockholder resales.
The attached update discloses a reduction of the Yorkville SEPA Floor Price from $1.00 to $0.50, and an additional Convertible Promissory Note advance of $0.50 million, yielding $0.45 million in net proceeds, with conversion at the lower of the fixed price or 95% of the 5‑day low VWAP, but not below $0.50, subject to a 9.99% ownership cap. The Nomura note was amended to reflect about $35.4 million principal and a limited waiver allowing up to $3.0 million of Yorkville convertible proceeds to fund operations. Nasdaq issued a delisting determination with trading suspension set for October 31, 2025, which the company plans to appeal. A 1‑for‑7 reverse split was effective September 1, 2025.
MSP Recovery, Inc. filed Prospectus Supplement No. 46 registering up to 285,715 shares of Class A common stock for potential resale by YA II PN, Ltd. (Yorkville) under its S-1. Sales by the selling stockholder will not deliver cash to the company, while MSP Recovery may receive proceeds from any shares it elects to sell to Yorkville under the Standby Equity Purchase Agreement.
The attached update notes a reduction of the Yorkville Floor Price from $1.00 to $0.50 and a new Convertible Promissory Note advance of $0.50 million, yielding net proceeds of $0.45 million. Nasdaq issued a Staff Delisting Determination to suspend trading on October 31, 2025; the company plans to request a hearing, and its shares may trade on the OTCQB Venture Market if delisted. A 1-for-7 reverse stock split took effect on September 1, 2025.
MSP Recovery (MSPR) disclosed multiple financing and listing updates. The company and Yorkville cut the SEPA and note Floor Price to $0.50. Under a second supplement, Yorkville agreed to provide up to $3.0 million in additional funding via Convertible Promissory Notes with a 10% original issue discount. On October 28, Yorkville advanced a note with $0.50 million principal, delivering $0.45 million in net proceeds. Notes may convert at the lower of the Fixed Price or 95% of the lowest 5‑day VWAP, but not below $0.50, and remain subject to a 9.99% ownership cap.
The company also amended and restated its Nomura note to reflect $35.4 million outstanding and obtained a limited waiver allowing up to $3.0 million of Yorkville note proceeds to be used for operations. Separately, Nasdaq issued a Staff Delisting Determination stating trading would be suspended on October 31, 2025 absent a successful appeal; MSPR plans to request a hearing and, if delisted, expects trading to continue on the OTCQB Venture Market.
MSP Recovery, Inc. entered a Second Supplemental Agreement with Yorkville that provides up to $3.0 million in additional funding through convertible promissory notes under an existing equity facility, with a 10% original issue discount and per-advance net principal increases capped at $1.0 million.
Yorkville may convert outstanding note balances into common stock at the lower of a fixed price or 95% of the lowest daily VWAP over five trading days, subject to a 9.99% ownership limit. As of October 10, 2025, the floor conversion price was reduced from $1.20 to $1.00 per share. The company also announced that General Counsel Alexandra Plasencia resigned effective October 17, 2025, and will advise through November 30, 2025, with no reported disagreements.
MSP Recovery, Inc. reported that on September 29, 2025, it entered into a material agreement with Yorkville to amend its existing Standby Equity Purchase Agreement (Yorkville SEPA). The change reduces the SEPA Floor Price from $1.60 to $1.20 per share, which is the minimum price at which shares can be sold to Yorkville under that arrangement. All capitalized terms used but not defined follow the meanings in the Yorkville SEPA and related notes.
MSP Recovery reports that it has entered into confidential settlement agreements in ongoing legal matters totaling $2.9 million in cash. Some of this cash will be shared with counterparties under the company’s existing participation and distribution agreements, so not all proceeds will stay with the company.
One preliminary mediated settlement with a property and casualty insurer includes a commitment to provide historical claims data, help reconcile current and future assigned Medicare claims, and make a cash payment to resolve historical claims. A separate confidential settlement was reached with a pharmaceutical defendant in litigation over alleged overpayments. Management notes that these settlements are still being finalized and warns that definitive agreements may not be executed or deliver the expected working capital or operational benefits.
MSP Recovery, Inc. filed an agreement change with its financing partner Yorkville to adjust terms under an existing Standby Equity Purchase Agreement. Effective September 15, 2025, the company and Yorkville agreed to reduce the SEPA “Floor Price” from $2.00 per share to $1.60 per share, as defined in the Yorkville SEPA and related notes. This modification affects the minimum share price at which equity can be issued under that arrangement but does not, by itself, change share counts or authorize new securities.
MSP Recovery, Inc. reports that its subsidiary MSP Recovery, LLC and Cano Health, LLC have entered into a written settlement agreement that fully and finally resolves all disputes between them in the Cano litigation. On September 9, 2025, both sides filed for dismissal with prejudice of all claims and counterclaims, and the court entered these dismissals without any admission of liability or wrongdoing by any party. As part of the settlement, each side expressly retracts and withdraws prior statements and allegations made about the others in connection with the dispute.
The company states it does not expect the dismissal of the Cano litigation to have a material impact on its financial condition or results of operations. It notes that previously disclosed risks tied to this litigation in its annual report for the year ended December 31, 2024 are eliminated as a result of the settlement and dismissal with prejudice.